Clinical Trials

Breast Neoplasms

NCT06075953 2026-03-16

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

400 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT01042379 2026-03-13

I-SPY

5,000 enrolled

BreastSarcoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

NCT07319429 2026-03-13

FEMUS

Phase 2/3 Recruiting

260 enrolled

Endometrial Neoplasms

NCT04293393 2026-03-12

CARABELA

200 enrolled 27 charts

Breast Neoplasms

NCT04886531 2026-03-12

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers

30 enrolled

Breast Neoplasms

NCT06218303 2026-03-12

Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ

Phase 1 Recruiting

50 enrolled

Carcinoma, Intraductal, Noninfiltrating

NCT02712723 2026-03-11

FELINE

121 enrolled 9 charts

Breast Neoplasms

NCT06671912 2026-03-04

LoTam

Phase 3 Suspended

1,156 enrolled

Phase NA Active not recruiting

Breast Carcinoma In Situ

NCT07448272 2026-03-04

PCOS OID

80 enrolled

Polycystic Ovary Syndrome

NCT04852887 2026-03-03

DEBRA

Phase 3 Recruiting

1,670 enrolled

Breast Neoplasms

NCT02767661 2026-02-27

MECCA

Phase 3 Completed

263 enrolled

Breast Neoplasms

NCT05467891 2026-02-27

RaPhLRR

200 enrolled

Locoregional Recurrence

NCT06179303 2026-02-27

Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

60 enrolled

Anatomic Stage III Breast Cancer AJCC v8

NCT07225790 2026-02-27

Emulation of the MONARCH-3 Trial Using Specialty Oncology Electronic Health Records Databases

Completed

3,883 enrolled

Advanced Breast Cancer

NCT02778685 2026-02-24

Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer

47 enrolled 17 charts

Breast Neoplasms

NCT03179904 2026-02-24

TVB-2640 and Trastuzumab With Paclitaxel or Endocrine Therapy for Treatment of HER2 Positive Metastatic Breast Cancer

17 enrolled 10 charts

Advanced Breast Carcinoma

NCT06507618 2026-02-24

POWER II

Phase 3 Recruiting

354 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT07394946 2026-02-20

NELOPHER

126 enrolled

Breast Neoplasms

NCT06348134 2026-02-17

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

74 enrolled

Breast Neoplasms

NCT03008408 2026-02-11

A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial Carcinoma

90 enrolled

Endometrial Neoplasms

NCT06366347 2026-02-11

ALPINE: Maintenance Letrozole/Abemaciclib

32 enrolled

Endometrial Neoplasms

NCT02520063 2026-02-06

Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer

Phase 1/2 Completed

15 enrolled 18 charts

Breast Neoplasms

NCT06143631 2026-02-03

PLUM

Phase 4 Recruiting

140 enrolled

Leiomyoma

NCT06394804 2026-02-03

CHAMELEON

20 enrolled

Low-Grade Serous Ovarian Cancer

NCT07178743 2026-01-30

Emulation of the PALOMA-2 Trial

Active not recruiting

6,097 enrolled

Advanced Breast Cancer

NCT03879577 2026-01-21

Assessing the Response Rate of Neo-adjuvant Taxotere and Trastuzumab in Nigerian Women With Breast Cancer

53 enrolled 13 charts

Breast Neoplasms

NCT07019363 2026-01-21

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)

Phase 3 Recruiting

1,903 enrolled

Breast Neoplasms

NCT04568616 2026-01-20

NAOMI

178 enrolled

Breast Neoplasms

NCT06001762 2026-01-16

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer

90 enrolled

Phase 3 Active not recruiting

Breast Neoplasms

NCT04095364 2026-01-14

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

450 enrolled

Phase 3 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04584853 2026-01-14

POETIC-A

123 enrolled

Breast Cancer Female

NCT05826964 2026-01-13

Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer

24 enrolled

Breast Neoplasms

NCT05150652 2026-01-07

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

8 enrolled

Breast Neoplasms

NCT06630325 2026-01-07

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

GastrointestinalGenitourinaryGynecologic

30 enrolled

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

NCT05286437 2025-12-30

LaPemERLA

40 enrolled

Phase 2 Not yet recruiting

Hormone Receptor-Positive HER2-Negative Advanced Breast Cancer

NCT07305246 2025-12-26

Clinical Study of SHR-A1811 With or Without Letrozole in Neoadjuvant Therapy for Early-Stage HR-Positive, HER2-Low Breast Cancer

120 enrolled

Breast Neoplasms

NCT05035836 2025-12-22

A Phase 2 Single-Arm Open-Label Pilot Trial Evaluating Zanidatamab (ZW25) in Patients With Early Stage HER2/Neu Positive (HER2+) Breast Cancer (BC)

20 enrolled

Breast Neoplasms

NCT07143682 2025-12-16

Letrozole Step up Protocol for Ovulation Induction in Infertile Women With Polycystic Ovary Syndrome

Phase 3 Completed

70 enrolled

Infertility, Polycystic Ovary Syndrome

NCT07285382 2025-12-16

Different Doses of Dalpicicl Combined With Letrozole in the First-line Treatment of HR-positive, HER2-negative Advanced Breast Cancer

120 enrolled

HR Positive HER2 Negative Advanced Breast Cancer

NCT04563507 2025-12-15

Combined Immunotherapies in Metastatic ER+ Breast Cancer

102 enrolled

Breast Neoplasms

NCT04603183 2025-12-12

ABIGAIL

Phase 2 Completed

162 enrolled

Breast Cancer Metastatic

NCT01068249 2025-11-18

Letrozole and RAD001 With Advanced or Recurrent Endometrial Cancer

42 enrolled 11 charts

Recurrence, Endometrial Neoplasms

NCT03079011 2025-11-18

PADA-1

Phase 3 Completed

1,017 enrolled

Breast Neoplasms

NCT06139107 2025-11-14

RADIANT: Pre-op Radiation With Abemaciclib and Letrozole

Phase 1 Recruiting

15 enrolled

Breast Neoplasms

NCT04569747 2025-11-13

ADEPT

375 enrolled

Breast Neoplasms

NCT01797523 2025-11-06

A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma

62 enrolled

Phase 1 Active not recruiting

Endometrial Neoplasms

NCT03959891 2025-09-29

AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)

77 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT02562118 2025-09-25

Neoadjuvant Lenvatinib Combined With Letrozole in Hormone Receptor Positive Breast Cancer

40 enrolled